BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Lupin formulation sales dip in Q4FY20

02 June 2020 | News

Q4 FY2020 sales were Rs 11,920 million, compared to sales of Rs 12,969 million during Q3 FY2020



Mumbai based Pharma major Lupin Limited has reported its financial performance for the quarter and fiscal year ending March 31, 2020. The gross profit was Rs 23,860 million compared to Rs 23,568 million in Q3 FY2020, with gross profit margin of 62.9 per cent.

The Personnel cost was 20.1 per cent of sales, at Rs 7,635 million compared to Rs 7,407 million in Q3 FY2020. The manufacturing and other expenses were 30.4 per cent of sales at Rs 11,519 million compared to Rs 12,402 million in Q3 FY2020. The investment in R&D for the quarter was Rs 3,442 million i.e. 9.1 per cent of sales.

Lupin’s India formulation sales for FY2020 were Rs 51,385 million, compared to Rs 46,382 million in FY 2019; accounting for 34 per cent of Lupin’s global sales. Q4 FY2020 sales were Rs 11,920 million, compared to sales of Rs 12,969 million during Q3 FY2020 and up 13 per cent compared to sales of Rs 10,525 million during Q4 FY2019.